Microliter-scale in vitro aerosol-cell delivery of inhalable antisense oligonucleotide (aso) induces “Burst-like” Pharmacokinetics

International Journal of Pharmaceutics X 2026 Open access

Read full text
Authors: Pramod Kumar, Ashesh Chakraborty, Elias Richter, Lin Yang, Andreas Schröppel, Coralie Mergault, Marion Blayac, Rita Vanbever, Laurent Plantier, Nathalie Heuzé-Vourch, Otmar Schmid
DOI: 10.1016/j.ijpx.2026.100588
Cited by: 1
References: 44

Abstract

Unlike traditional submerged cell cultures, nebulized drug delivery to air-liquid interface (ALI)-cultured lung cells provides a clinically relevant route for in vitro testing of inhalable drugs. Current nebulizer systems deliver non-physiologically large drug volumes. Here, we introduce the Cloud MAX technology, characterize its accuracy of dosimetry, and apply it to toxicity, efficacy, and biokinetics or permeability testing of a locked nucleic acid-modified antisense oligonucleotide (ASO). On average the Cloud MAX delivers 44% of 3–20 μL aerosolized liquid to ALI-cultured cells, the coefficient of variation (CV) of repeated drug dosing is

Fields of Study & Subjects

Inhalation and Respiratory Drug Delivery Extracellular vesicles in disease Graphene and Nanomaterials Applications

Publication details

Journal / source
International Journal of Pharmaceutics X
Publisher
Elsevier BV
Pages
100588–100588
Publication date
1 July 2026
Language
EN